Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device (UPLUG-SAFE)
Primary Purpose
Hemodialysis, Renal Insufficiency, Chronic
Status
Recruiting
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
UPLUG Hemodialysis Connection Device
Sponsored by
About this trial
This is an interventional device feasibility trial for Hemodialysis focused on measuring medical device, connection medical device
Eligibility Criteria
Inclusion Criteria:
- with end-stage chronic renal failure treated by hemodialysis (2 or 3 sessions per week)
- Wearer of a right or left jugular permanent tunneled central venous hemodialysis catheter whose end has been in the superior vena cava or the right atrium for at least 1 month
- Hemodialysis catheter lock used = heparin or 4% citrate
- Expected life expectancy > 6 months
- Dialysis session preceding inclusion with an average blood flow of at least 300ml/min
Exclusion Criteria:
- Patient with a mechanical heart valve
- Patient with an arteriovenous fistula (AVF) that can be used within one month
- Kidney transplant by living donor planned in the following month
- Pregnant or breastfeeding woman
- History of infection on the hemodialysis catheter in place dating from less than 6 months
- Psychiatric or demented patient unable to obtain informed consent
- Patient already included in another protocol
Sites / Locations
- CHU Caen NormandieRecruiting
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
use of the device during hemodialysis sessions
Arm Description
use of the device during one month during hemodialysis sessions
Outcomes
Primary Outcome Measures
success in performing dialysis
Study the feasibility of performing dialysis with the UPlug Technology in patients with a permanent tunneled central venous hemodialysis catheter with the objective of a success rate ≥ 80%.
Secondary Outcome Measures
Number of participants with Adverse Events [Safety and Tolerability] of the experimental device UPLUG
adverse events reported from consent to end of study
experimental device integrity
device deficiencies reported from consent to end of study
nurses' satisfaction
satisfaction evaluated by questionnaire before and after the inclusions
patient satisfaction
satisfaction evaluated by questionnaire before and after the use of experimental device
clinical performance of device
performance measured by rate of successful sessions
Full Information
NCT ID
NCT05419258
First Posted
April 29, 2022
Last Updated
July 31, 2023
Sponsor
University Hospital, Caen
1. Study Identification
Unique Protocol Identification Number
NCT05419258
Brief Title
Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device
Acronym
UPLUG-SAFE
Official Title
Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device
Study Type
Interventional
2. Study Status
Record Verification Date
July 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 6, 2022 (Actual)
Primary Completion Date
October 2023 (Anticipated)
Study Completion Date
October 2023 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Caen
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.
Aim:
The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.
Material and methods:
This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.
Hypothesis tested:
The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.
Detailed Description
The incidence and prevalence of chronic insufficiency have been growing for several years. Increasingly older patients are treated with chronic hemodialysis. The vascular access of choice remains the arteriovenous fistula and the proportion of hemodialysis patients on the permanent central venous hemodialysis catheter varies from 20 to 35% in dialysis centres. The new Uplug° technology, interface between the end of the hemodialysis catheter and the dialysis circuit, makes it possible to limit direct access to the hemodialysis catheter during connections and disconnections.
Aim:
The investigators propose a feasibility study, in order to study the new Uplug° technology in real conditions of use.
Material and methods:
This study aim to include 15 hemodialysis patients in a center on a tunneled permanent central venous hemodialysis catheter. The inclusion period is three months. The follow-up time for each participant is 6 weeks. Patients with a tunneled permanent central venous hemodialysis catheter and performing dialysis sessions with a flow rate ≥ 300 ml/min may be included. The Uplug° technology will be placed at the end of each patient's hemodialysis catheter for a period of one month.
Hypothesis tested:
The main endpoint is the proportion of hemodialysis sessions performed successfully with this technology, respecting the usual dialysis prescription.
The secondary objectives are the infectious risk, the defects of the experimental device and the hemodialysis catheter or their implementation, the satisfaction of the nursing staff and the patient, the reduction in the number of manipulations and the effective time of these manipulations.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hemodialysis, Renal Insufficiency, Chronic
Keywords
medical device, connection medical device
7. Study Design
Primary Purpose
Device Feasibility
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Model Description
feasibility study on medical device
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
use of the device during hemodialysis sessions
Arm Type
Experimental
Arm Description
use of the device during one month during hemodialysis sessions
Intervention Type
Device
Intervention Name(s)
UPLUG Hemodialysis Connection Device
Intervention Description
use of the device UPLUG during 1 month
Primary Outcome Measure Information:
Title
success in performing dialysis
Description
Study the feasibility of performing dialysis with the UPlug Technology in patients with a permanent tunneled central venous hemodialysis catheter with the objective of a success rate ≥ 80%.
Time Frame
one month
Secondary Outcome Measure Information:
Title
Number of participants with Adverse Events [Safety and Tolerability] of the experimental device UPLUG
Description
adverse events reported from consent to end of study
Time Frame
one month
Title
experimental device integrity
Description
device deficiencies reported from consent to end of study
Time Frame
one month
Title
nurses' satisfaction
Description
satisfaction evaluated by questionnaire before and after the inclusions
Time Frame
one month
Title
patient satisfaction
Description
satisfaction evaluated by questionnaire before and after the use of experimental device
Time Frame
one month
Title
clinical performance of device
Description
performance measured by rate of successful sessions
Time Frame
one month
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
with end-stage chronic renal failure treated by hemodialysis (2 or 3 sessions per week)
Wearer of a right or left jugular permanent tunneled central venous hemodialysis catheter whose end has been in the superior vena cava or the right atrium for at least 1 month
Hemodialysis catheter lock used = heparin or 4% citrate
Expected life expectancy > 6 months
Dialysis session preceding inclusion with an average blood flow of at least 300ml/min
Exclusion Criteria:
Patient with a mechanical heart valve
Patient with an arteriovenous fistula (AVF) that can be used within one month
Kidney transplant by living donor planned in the following month
Pregnant or breastfeeding woman
History of infection on the hemodialysis catheter in place dating from less than 6 months
Psychiatric or demented patient unable to obtain informed consent
Patient already included in another protocol
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Maxence FICHEUX
Phone
0231063106
Email
ficheux-m@chu-caen.fr
Facility Information:
Facility Name
CHU Caen Normandie
City
Caen
ZIP/Postal Code
14000
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Maxence FICHEUX
Phone
0231063106
Email
ficheux-m@chu-caen.fr
12. IPD Sharing Statement
Plan to Share IPD
Yes
Learn more about this trial
Feasibility and Evaluation Study of the UPLUG Hemodialysis Connection Device
We'll reach out to this number within 24 hrs